-
Oligo (dT) 25 Beads for Immune-Cell RNA Workflows
2026-09-17
Oligo (dT) 25 Beads provide a selective, magnet-assisted route from total RNA or eukaryotic cells to polyadenylated mRNA for cDNA, RT-PCR, and sequencing workflows. This practical guide connects immune-aging research with sample-preparation decisions, including bead handling, direct cDNA synthesis, quality control, and troubleshooting.
-
NSC-23766: A Rac1 Assay Decision Framework
2026-09-17
NSC-23766 is a Rac GTPase inhibitor that links Rac1-GEF biology to interpretable cancer and cell-signaling assays. This evidence-based guide explains how to distinguish target engagement from downstream toxicity, using breast cancer combination data to improve experimental decisions.
-
Ambroxol Targets Nav1.8, TRPV1, and TRPA1
2026-09-16
A 2025 Journal of Pain study used whole-cell patch clamp recordings to define how ambroxol modulates human and rat Nav1.8, TRPV1, and TRPA1 channels. Its strongest mechanistic result was pronounced species dependence at Nav1.8, while additional TRPV1 and TRPA1 effects provide a plausible, but still preclinical, basis for topical neuropathic pain research.
-
Novobiocin Sodium: DNA Replication Workflows
2026-09-16
Novobiocin Sodium provides a practical way to separate bacterial DNA replication arrest from genomic DNA degradation while linking replication status to membrane growth and vacuole formation. This workflow translates a time-resolved Enterococcus faecalis protoplast study into reproducible microscopy, qPCR, washout, and antibiotic-resistance experiments.
-
Oridonin Protects Bone Through MAPK/NF-κB and BMP-2
2026-09-15
The reference study identifies oridonin as a dual-action candidate that suppresses thioacetamide-induced osteoclastogenesis while restoring osteoblast differentiation. Its mechanistic contribution is the connection of MAPK/NF-κB signaling in bone resorption with BMP-2/RUNX2 signaling in bone formation, providing a framework for studying therapies that address both sides of skeletal remodeling.
-
Telatinib: Mapping VEGF Signaling in TNBC
2026-09-15
Telatinib (BAY 57-9352) offers a multitarget framework for studying angiogenesis, invasion, and tumor-cell signaling in triple-negative breast cancer. This thought-leadership guide connects receptor-level pharmacology with phenotype-driven validation and translational decision-making.
-
Tetramethylrhodamine ethyl ester perchlorate assays
2026-09-14
Use TMRE to convert mitochondrial membrane-potential changes into actionable live-cell imaging and flow-cytometry data. This guide connects practical staining workflows with a new caspase-3/NDUFS1 mechanism implicated in trichothecene-induced liver injury, while highlighting controls and troubleshooting steps that prevent overinterpretation.
-
DiscoveryProbe™ Immunology Library: Assay Strategy
2026-09-14
The DiscoveryProbe Immunology/Inflammation Compound Library supports a decision-focused strategy for target validation, immune pathway profiling, and phenotypic screening. Learn how to combine its chemically diverse 295-compound set with multiplex PBMC measurements to distinguish genuine immunomodulation from cytotoxicity and assay artifacts.
-
TMEM16F Lipid Scrambling Shapes Ferroptosis Immunity
2026-09-13
Yang et al. identify TMEM16F-mediated plasma-membrane lipid scrambling as a late-stage suppressor of ferroptosis. Loss or inhibition of this process promotes membrane collapse, danger-signal release, tumor control, and stronger responses to PD-1 blockade, highlighting membrane mechanics as an immunologically relevant layer of ferroptosis biology.
-
Patient-Derived Gastric Cancer Assembloid Model
2026-09-12
Shapira-Netanelov and colleagues developed gastric cancer assembloids that combine patient-matched tumor organoids with tumor-derived stromal subpopulations. The model captures microenvironment-dependent gene expression and drug-response differences that are not apparent in organoid monocultures, strengthening its value for personalized cancer biology research.
-
Ibotenic Acid Workflows for Neurodegeneration Models
2026-09-11
Build more interpretable excitotoxicity and circuit-mapping experiments with Ibotenic acid, an NMDA receptor agonist whose dual glutamatergic activity supports disease modeling. A time-resolved workflow separates early neuronal activation from later injury, while practical solubility, control, and troubleshooting guidance improves reproducibility.
-
DAPI Nuclear Stain Solution: Practical Guide
2026-09-11
DAPI (4',6-Diamino-2-Phenylindole) Nuclear Stain Solution, SKU K2402, provides a ready-to-use fluorescent DNA binding dye for nuclear visualization, endpoint cell viability assessment, and apoptosis-related nuclear evaluation. Its weak cell permeability makes it more appropriate for fixed or membrane-compromised samples than for routine staining of intact live cells.
-
SMPD4, Ceramide, and Primary Cilia in Brain Development
2026-09-10
The 2024 Development study identifies SMPD4-dependent ceramide production as a mechanistic link between sphingolipid metabolism, primary cilium integrity, and brain development. Using a mouse model and SMPD4-deficient human induced pluripotent stem cells, the authors connect ceramide deficiency with cerebellar hypoplasia, neural progenitor loss, and shortened cilia, while showing that exogenous ceramide can rescue the ciliary phenotype.
-
KR-12 Design, Mechanisms, and Translational Potential
2026-09-10
The 2024 review on KR-12 presents this LL-37-derived fragment as a compact platform for membrane-targeting antimicrobial, antibiofilm, endotoxin-neutralizing, and immune-regulatory research. Its central innovation is the systematic use of peptide engineering, formulation, and biomaterial immobilization to address the activity, stability, and delivery limitations of native KR-12.
-
BFH772 (VEGFR2 inhibitor): Workflow Guide
2026-09-09
BFH772 is a selective small-molecule VEGFR2 inhibitor for biochemical, cellular, and tumor angiogenesis research where organic-solvent compatibility and target-focused pathway modulation are required. It should not be selected for water-soluble assay systems or interpreted as a broad-spectrum kinase inhibitor without an appropriate counter-screen.